

REMARKS**STATUS OF THE CLAIMS**

The Office has required a restriction pursuant to 35 U.S.C. §121. The following twelve inventions have been identified:

Group I: Claims 1, 2, 14-25 and 32-47, are drawn to a process of preparing compounds of the formula (I).

Group II: Claims 13-7 are drawn to a process of preparing compounds of the formula (II).

Group III: Claim 8 is drawn to a process of preparing compounds of the formula (IV).

Group IV: Claims 9 and 10 are drawn to a process of preparing compounds of the formula (V).

Group V: Claims 9 and 10 are drawn to a process of preparing compounds of the formula (V).

Group VI: Claim 11 is drawn to a process of preparing compounds of the formula (VI).

Group VII: Claim 12 is drawn to a process of preparing compounds of the formula (VI).

Group VIII: Claim 13 is drawn to a process of preparing compounds of the formula (VII).


Group IX: Claims 26-28 are drawn to a process of preparing compounds of the formula (XVII).

Group X: Claim 29 is drawn to a product of the formula (II).

Group XI: Claims 30, 47 and 48 are drawn to a product of the formula (IV).

Group XII: Claim 31 is drawn to a product of the formula (V).

Subject to the foregoing, Applicants elect the invention of Group II and elect the species of Example 15 having the following structure:



3-isopropyl-6-[4-bromo-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine

without traverse. The election is without prejudice to Applicants' right to file divisional applications directed to the subject matter not contained therein.

To comply with Requirement for Restriction, claims 1, 2, and 8-48 have been withdrawn.


With respect to the requirement for restriction between Groups I-XII, Applicants elect to follow the procedure set forth in MPEP 821.04 and "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. §103(b)", 1184 Off. Gazette 86 (1996), which permits rejoinder of method claims upon the allowance of a claim to the composition of matter.

Conclusion

Claims 1, 2, and 8-48 have been withdrawn. It is believed that the pending claims are in condition for allowance, it is respectfully requested that the application be passed to issue.

If the Examiner believes a telephonic interview with Applicant's representative would aid in the prosecution of this application, the examiner is cordially invited to contact Applicant's representative at the below listed number.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Julie M. Lappin".

Julie M. Lappin, Reg. No. 46,612

Pharmacia Corporation
of Pfizer, Inc
P.O. Box 1027
Chesterfield, MO 63006
(314) 274-2009
(314) 274-9095 (facsimile)